Targeting the MET oncogene in cancer and metastases

By Stella Giulia M   Benvenuti Silvia   Comoglio Paolo M  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1381-1394

Informa Healthcare

Access to resources Recommend Favorite

1 -Adrenoceptor subtype activation increases proto-oncogene mRNA levels. Role of protein kinase C

By Garca-Sainz J.A.   Alcantara-Hernandez R.   Vazquez-Prado J.  

European Journal of Pharmacology, Vol. 342, Iss. 2, 1998-01 ,pp. : 311-317

Elsevier

Access to resources Recommend Favorite

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

By Kang Yoon-Koo   Muro Kei   Ryu Min-Hee   Yasui Hirofumi   Nishina Tomohiro   Ryoo Baek-Yeol   Kamiya Yukimasa   Akinaga Shiro   Boku Narikazu  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 355-361

Springer Publishing Company

Access to resources Recommend Favorite

Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

By  

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 940-950

Bentham Science Publishers

Access to resources Recommend Favorite

INDUCTION OF c-myc AND c-jun PROTO-ONCOGENE EXPRESSION IN RAT L6 MYOBLASTS BY CADMIUM IS INHIBITED BY ZINC PREINDUCTION OF THE METALLOTHIONEIN GENE

By Abshire Michael K.   Buzard Gregory S.   Shiraishi Noriyuki   Waalkes Michael P.  

Journal of Toxicology and Environmental Health, Vol. 48, Iss. 4, 1996-07 ,pp. : 359-378

Taylor & Francis Ltd

Access to resources Recommend Favorite